Zobrazeno 1 - 10
of 136
pro vyhledávání: '"J. F. Apperley"'
Autor:
D. Rea, A. Hochhaus, M. J. Mauro, Y. Minami, E. Lomaia, S. Voloshin, A. Turkina, D.-W. Kim, J. F. Apperley, J. E. Cortes, A. Abdo, L. M. Fogliatto, D. D. H Kim, P. le Coutre, S. Saussele, M. Annunziata, T. P. Hughes, N. Chaudhri, L. Chee, V. García-Gutiérrez, K. Sasaki, S. Kapoor, A. Allepuz, S. Quenet, V. Bédoucha, C. Boquimpani
Publikováno v:
HemaSphere, Vol 6, Pp 56-57 (2022)
Externí odkaz:
https://doaj.org/article/c727b28a8e3f4a6499d00c970fd97e02
Autor:
G. Nesr, R. Szydlo, B. Braithwaite, S. Frackelton, P. Mathew, M. Hashmi, F. Fernando, A. Innes, S. Claudiani, A. Khan, A. Rao, L. Foroni, D. Milojkovic, J. F. Apperley, R. E. Clark
Publikováno v:
HemaSphere, Vol 6, Pp 608-609 (2022)
Externí odkaz:
https://doaj.org/article/81401e6fcac340b6a10235d495596fbc
Publikováno v:
HemaSphere, Vol 6, Pp 609-610 (2022)
Externí odkaz:
https://doaj.org/article/83cacdc274514a90bb7d9a6af438f27d
Autor:
Eduardo Olavarria, Edward Kanfer, J. F. Apperley, R Palani, Aristeidis Chaidos, B Sevillano, F O'Boyle, Dragana Milojkovic, C Jakob, Oscar M. Pello, Amin Rahemtulla, Donald Macdonald, Richard Szydlo, A Bradshaw, Jiří Pavlů, Holger W. Auner
Publikováno v:
Bone marrow transplantation. 52(12)
Hematopoietic precursor cells (HPC) are able to restore hematopoiesis after high-dose chemotherapy and their cryopreservation is routinely employed prior to the autologous hematopoietic cell transplantation (AHCT). Although previous studies showed fe
Autor:
N. Mikhailova, Kai Hübel, Nina Worel, Zdenek Koristek, Francesco Lanza, Mahmoud Aljurf, Roberto M. Lemoli, Gabor Mikala, Laurent Garderet, J. F. Apperley, Grzegorz W. Basak, N Kröger, Patrick Wuchter, Michael W. Kattan, Harry C. Schouten, Arnon Nagler, Ali Bazarbachi, Ian H Gabriel, D Selleslag, K. Douglas, Ozren Jakšić, Anna Sureda, Christian Chabannon, R. F. Duarte, Stefan Suciu, Catarina Geraldes, L. Mendeleeva, M. Mohty
Publikováno v:
Bone Marrow Transplantation, 49(7), 865-872. Nature Publishing Group
Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow Transplantation develo
Autor:
R. F. Duarte, Gérard Socié, Mohamad Mohty, Tapani Ruutu, Hildegard T. Greinix, Wieslaw Wiktor-Jedrzejczak, Laurent Garderet, Olle Ringdén, Almalina Bacigalupo, T. de Witte, Dietger Niederwieser, Jürgen Finke, Kröger N, Jorge Sierra, Alejandro Madrigal, Ernst Holler, Anita Lawitschka, Anna Sureda, Jakob Passweg, J. F. Apperley, Alois Gratwohl, Arnon Nagler, Peter Dreger, Francesco Dazzi, Boris V. Afanasyev
Publikováno v:
Bone Marrow Transplantation, 49, 168-73
BONE MARROW TRANSPLANTATION
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Bone Marrow Transplantation, 49, 2, pp. 168-73
BONE MARROW TRANSPLANTATION
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Bone Marrow Transplantation, 49, 2, pp. 168-73
Item does not contain fulltext GVHD remains the major impediment to broader application of allogeneic haematopoietic SCT. It can be prevented completely, but at the expense of other complications, rejection, relapse or delayed immune reconstitution.
Multiple myeloma is a haematological malignancy characterized by an expansion of malignant plasma cells within the bone marrow and is frequently associated with bone disease involving the development of osteolytic bone lesions, pathological fractures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8722a53f71a57bef7bf92f7ffce82353
https://ora.ox.ac.uk/objects/uuid:6298a869-0247-40bb-8e7f-14d639a95c99
https://ora.ox.ac.uk/objects/uuid:6298a869-0247-40bb-8e7f-14d639a95c99
Autor:
Andreas Hochhaus, J. F. Apperley, Gert J. Ossenkoppele, Francis J. Giles, Neil Gallagher, P. le Coutre, Yaping Shou, Michele Baccarani, Hagop M. Kantarjian, Jorge E. Cortes, Rick E. Blakesley
Publikováno v:
Leukemia, 26(6), 1189-1194. Nature Publishing Group
le Coutre, P, Giles, F, Hochhaus, A, Apperley, J, Ossenkoppele, G J, Blakesley, R, Shou, Y, Gallagher, N, Baccarani, M, Cortes, J & Kantarjian, H 2012, ' Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results ', Leukemia, vol. 26, no. 6, pp. 1189-1194 . https://doi.org/10.1038/leu.2011.323
le Coutre, P, Giles, F, Hochhaus, A, Apperley, J, Ossenkoppele, G J, Blakesley, R, Shou, Y, Gallagher, N, Baccarani, M, Cortes, J & Kantarjian, H 2012, ' Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results ', Leukemia, vol. 26, no. 6, pp. 1189-1194 . https://doi.org/10.1038/leu.2011.323
Nilotinib (Tasigna) is a potent and selective BCR-ABL inhibitor approved for use in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CML-CP) and in patients with CML-CP and accelerated phase (CML-AP) who are resistant to
Autor:
Corinne Hedgley, Kate Stringaris, H de Lavallade, Ruhena Sergeant, Katy Rezvani, Marco Bua, J. Davis, J. M. Goldman, Abdullah Alsuliman, Stephen G. O'Brien, Deborah B. Marin, Nichola Cooper, Letizia Foroni, Jamshid S. Khorashad, Richard E. Clark, S Ahmad, Dragana Milojkovic, Ahmad Khoder, Ian H Gabriel, J. F. Apperley
Publikováno v:
Leukemia. 26:296-302
Natural killer (NK) cells are expanded in chronic myeloid leukemia (CML) patients on tyrosine kinase inhibitors (TKI) and exert cytotoxicity. The inherited repertoire of killer immunoglobulin-like receptors (KIR) may influence response to TKI. We inv
Publikováno v:
Bone Marrow Transplantation. 47:568-573
We have audited the invitation for uptake and outcome of artificial reproductive techniques in patients undergoing SCT for haematological malignancy, with the aim of improving our pre-transplant counselling. A postal survey was sent to 434 patients i